United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - ursodeoxycholic acid - oral tablet - 150mg

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; purified talc; polysorbate 80; hypromellose; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; macrogol 6000 - treatment of chronic cholestatic liver diseases

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; polysorbate 80; crospovidone; purified talc; macrogol 6000; magnesium stearate; povidone; colloidal anhydrous silica; hypromellose - the treatment of chronic cholestatic liver diseases

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: maize starch; colloidal anhydrous silica; pregelatinised maize starch; magnesium stearate; titanium dioxide; gelatin; sodium lauryl sulfate; sorbitan monolaurate - ursosan is indicated in the treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; titanium dioxide; maize starch; gelatin; sodium lauryl sulfate; magnesium stearate; purified water - the treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule - excipient ingredients: silicon dioxide; gelatin; titanium dioxide; maize starch; magnesium stearate - ursodeoxycholic acid is indicated in the treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: maize starch; magnesium stearate; colloidal anhydrous silica; titanium dioxide; sorbitan monolaurate; gelatin; sodium lauryl sulfate - ursodox lupin (ursodeoxycholic acid) capsule is indicated in the treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; maize starch; magnesium stearate; titanium dioxide; iron oxide yellow; gelatin - ursodox lapl (ursodeoxycholic acid) capsule is indicated in the treatment of chronic cholestatic liver diseases.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amdipharm ltd. - ursodeoxycholic acid 250 mg - capsule, hard - 250 mg - ursodeoxycholic acid 250 mg - liver therapy, lipotropics; a05aa02 ursodeoxycholic acid

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - ursodeoxycholic acid - oral tablet - 150mg